Junaxo has a portfolio of compounds that are being developed for the treatment of neurological disorders.

The compounds that Junaxo researches

  • are single-chemical entities
  • are clinical-trial ready
  • are novel, first-in-class treatments
  • target serious, unmet clinical needs

JNX1001 is being developed for amyotrophic lateral sclerosis (ALS) [more]

JNX3001 is being developed for disease modification in Parkinson's disease [more]

JNX4022 is being developed for dyskinesia in Parkinson's disease [more]

Junaxo has secured funding that will allow it to reach important scientific and commercial milestones.

Funding is still being sought for our clinical programs and interested parties should contact us at info@junaxo.com